Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Mole101on May 14, 2021 8:37pm
184 Views
Post# 33208863

RE:RE:Three Weeks To Decision Day...

RE:RE:Three Weeks To Decision Day...

Share price will be affected by Biogen decision up/ down and it will affect future PPs and their valuation .. like it or know We are affected by that decision and I rather see .40 because of an FDA ok with conditions that a .08 again with a No from FDA . .. I'm allowed to dream right? ;)


quote=M101]We wait, we wait, we wait, why? Look at Gene and Elliot jingle the shiny keys to the new Aducanumab.   

These clowns had to slash operations 80% even after blowing a banker and we're talking about Biogen's regulatory capture gambit? 

Clinical trials is what matters, not that you'd know from the MD&A. 


[/quote]
 

<< Previous
Bullboard Posts
Next >>